<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157976</url>
  </required_header>
  <id_info>
    <org_study_id>MRVT-920101-OPH005</org_study_id>
    <nct_id>NCT00157976</nct_id>
  </id_info>
  <brief_title>Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration</brief_title>
  <official_title>A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miravant Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miravant Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX)
      photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal
      neovascularization (CNV) associated with age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic changes</measure>
  </secondary_outcome>
  <enrollment>660</enrollment>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photrex (rostaporfin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with age greater than or equal to 50 years with at least one subfoveal CNV
        membrane secondary to AMD that can be demonstrated by fluorescein angiography.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy J. Snyder, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Miravant Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miravant Pharmaceuticals</last_name>
    <phone>1-800-685-2959</phone>
    <email>ctinfo@miravant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple Investigators</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiple Investigators</name>
      <address>
        <city>Brno-Bohunice, Olomouc, Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiple Investigators</name>
      <address>
        <city>Warsaw, Bydgoszcz, Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiple Investigators</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>November 29, 2005</last_update_submitted>
  <last_update_submitted_qc>November 29, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2005</last_update_posted>
  <keyword>Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>Visual Acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

